Marseille, October 22, 2007 - Innate Pharma SA, a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, today announced that it has received approval from the French authorities to start an exploratory Phase II (“Phase IIa”) clinical trial in chronic myeloid leukemia* (“CML”) with IPH 1101, the lead drug candidate of its γδ T cell platform... Innate Pharma's Press Release [PDF]- Communiqué de Presse d'Innate Pharma en français [PDF]-
Tuesday, October 23, 2007
INNATE PHARMA, NEW PHASE IIa TRIAL WITH IPH 1101 IN CHRONIC MYELOID LEUKEMIA
Marseille, October 22, 2007 - Innate Pharma SA, a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, today announced that it has received approval from the French authorities to start an exploratory Phase II (“Phase IIa”) clinical trial in chronic myeloid leukemia* (“CML”) with IPH 1101, the lead drug candidate of its γδ T cell platform... Innate Pharma's Press Release [PDF]- Communiqué de Presse d'Innate Pharma en français [PDF]-
